who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How Medtronic (MDT) makes money: Q1 2027 revenue breakdown

US GAAP, Q1 2027 · released Sep 1

Net Income (Medtronic)

$1,470M

up 41.4% y/y

Revenue

$9,756M

up 13.7% y/y

Operating Profit

$1,764M

up 22.1% y/y

Next report

Nov 24

date announced

The quarter in brief

Broad-based growth — revenue up 13.7% with every portfolio growing double digits, led by Electrophysiology (+29.5%) — though an extra 53rd fiscal week added roughly $570M of that growth; GAAP net income jumped 41.4% helped by a minority-investment swing and a lower tax rate, while non-GAAP EPS grew a more modest 15.1%.

Key growth driver: Cardiovascular — the fastest-growing revenue line: $3,927, +20% y/y. · by the Q1 2027 report

How does Medtronic make money?

Medtronic brought in $9.76 billion of revenue in Q1 2027, up 13.7% year over year. The largest source was Cardiovascular: $3.93 billion, or 40% of the total, followed by Neuroscience ($2.68B, 27%) and Medical Surgical ($2.28B, 23%); other lines add the remaining 9%. Net income for the quarter was $1.47 billion, up 41.4% year over year.

Revenue by source, Q1 2027
  • Cardiovascular$3.93B · 40% · +19.5%
  • Neuroscience$2.68B · 27% · +10.3%
  • Medical Surgical$2.28B · 23% · +10.0%
  • Diabetes$843M · 9% · +16.9%
  • Other$29.0M · 0.3% · −59.7%

Shares of $9.76B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of MDT (Medtronic) earnings report for Q1 2027: revenue, costs and profitCardiovascular$3,927 · +19.5%Neuroscience$2,678 · +10.3%Medical Surgical$2,279 · +10.0%Diabetes$843 · +16.9%Other$29 · −59.7%Revenue$9,756 · +13.7%Cost of ProductsSold$3,416 · +13.8%Gross Profit$6,340 · +13.7%65.0% marginR&D$771 · +6.2%SG&A$3,198 · +14.0%Amortization$412 · −10.2%non-cash*Restructuring$72 · +60.0%Other operatingexpense$123 · +75.7%Operating Profit$1,764 · +22.1%18.1% marginOthernon-operatingincome$190Interest expense,net$186 · +5.7%Pre-Tax Income$1,769 · +35.9%Income Tax$289 · +13.3%Noncontrolling Interests$9Net Income (Medtronic)$1,470 · +41.4%$1.14 diluted EPS
Sankey diagram of MDT (Medtronic) earnings report for Q1 2027: revenue, costs and profit
Line itemAmount and change
Cardiovascular$3,927 · +19.5%
Neuroscience$2,678 · +10.3%
Medical Surgical$2,279 · +10.0%
Diabetes$843 · +16.9%
Other$29 · −59.7%
Revenue$9,756 · +13.7%
Cost of Products Sold$3,416 · +13.8%
Gross Profit$6,340 · +13.7% · 65.0% margin
R&D$771 · +6.2%
SG&A$3,198 · +14.0%
Amortization$412 · −10.2% · non-cash*
Restructuring$72 · +60.0%
Other operating expense$123 · +75.7%
Operating Profit$1,764 · +22.1% · 18.1% margin
Other non-operating income$190
Interest expense, net$186 · +5.7%
Pre-Tax Income$1,769 · +35.9%
Income Tax$289 · +13.3%
Noncontrolling Interests$9
Net Income (Medtronic)$1,470 · +41.4% · $1.14 diluted EPS

Verdict: broad-based growth — revenue up 13.7% with every portfolio growing double digits, led by Electrophysiology (+29.5%) — though an extra 53rd fiscal week added roughly $570M of that growth; GAAP net income jumped 41.4% helped by a minority-investment swing and a lower tax rate, while non-GAAP EPS grew a more modest 15.1%.

Q1 OCF $1,793M (+64.8%), FCF $1,290M (+120.9%); dividends $921M, buybacks $267M, acquisitions $1,162M (Scientia Vascular, SPR Therapeutics); FY27 guidance raised: organic revenue growth 7.25–7.75%, non-GAAP EPS $5.94–$6.00.

Source and notation

* marks non-cash / ≈ estimated. Source: Medtronic plc press release / 10-Q (SEC EDGAR).

Open as an image: Medtronic (MDT), Q1 2027 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Medtronic (MDT) Q1 2027: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mdt. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/mdt"><img src="https://whoreportstoday.com/t/mdt/img/medtronic-mdt-earnings-sankey.png" alt="Medtronic (MDT) Q1 2027: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/mdt">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/mdt/img/medtronic-mdt-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/mdt">Medtronic (MDT) Q1 2027 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Medtronic plc is an international medical device company. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue.

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2027revenue growth +7…8% (raised)EPS (non-GAAP) $5.94–6.00 (raised)revenue $36.4BEPS (GAAP) $3.73—

Same quarter a year ago (ended October 24, 2025): revenue $8.96B, EPS (GAAP) $1.07

How we calculate

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Sep 1, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

MDT earnings history: past report dates

Sep 1, 2026 Tue6:47 ambefore market openJul 31, 2026$9.8B+14% y/y$1.14+41% y/y
Jun 3, 2026 Wed6:47 ambefore market openApr 24, 2026≈$9.8B+10% y/y≈$0.96+19% y/y
Feb 17, 2026 Tue6:48 ambefore market openJan 23, 2026$9.0B+9% y/y$0.89−12% y/y
Nov 18, 2025 Tue6:47 ambefore market openOct 24, 2025$9.0B+7% y/y$1.07+8% y/y
Aug 19, 2025 Tue6:49 ambefore market openJul 25, 2025$8.6B+8% y/y$0.81+1% y/y
May 21, 2025 Wed6:47 ambefore market openApr 25, 2025≈$8.9B+4% y/y≈$0.81+62% y/y
Feb 18, 2025 Tue6:46 ambefore market openJan 24, 2025$8.3B+3% y/y$1.01+2% y/y
Nov 19, 2024 Tue6:46 ambefore market openOct 25, 2024$8.4B+5% y/y$0.99+46% y/y
Aug 20, 2024 Tue6:46 ambefore market openJul 26, 2024$7.9B+3% y/y$0.80+36% y/y
May 23, 2024 Thu6:47 ambefore market openApr 26, 2024≈$8.6B+1% y/y≈$0.50−43% y/y
Feb 20, 2024 Tue6:47 ambefore market openJan 26, 2024$8.1B+5% y/y$0.99+8% y/y
Nov 21, 2023 Tue6:53 ambefore market openOct 27, 2023$8.0B+5% y/y$0.68+113% y/y
Aug 22, 2023 Tue6:47 ambefore market openJul 28, 2023$7.7B+4% y/y$0.59−16% y/y
May 25, 2023 Thu6:48 ambefore market openApr 28, 2023≈$8.5B+6% y/y≈$0.88−20% y/y
Feb 21, 2023 Tue6:48 ambefore market openJan 27, 2023$7.7B−0% y/y$0.92−16% y/y
Nov 22, 2022 Tue6:47 ambefore market openOct 28, 2022$7.6B−3% y/y$0.32−67% y/y
Aug 23, 2022 Tue6:47 ambefore market openJul 29, 2022$7.4B−8% y/y$0.70+25% y/y
May 26, 2022 Thu6:49 ambefore market openApr 29, 2022≈$8.1B−1% y/y≈$1.10+10% y/y
Feb 22, 2022 Tue6:47 ambefore market openJan 28, 2022$7.8B−0% y/y$1.10+17% y/y
Nov 23, 2021 Tue6:49 ambefore market openOct 29, 2021$7.8B+3% y/y$0.97+169% y/y
Aug 24, 2021 Tue6:50 ambefore market openJul 30, 2021$8.0B+23% y/y$0.56+56% y/y
May 27, 2021 Thu6:46 ambefore market openApr 30, 2021≈$8.2B+37% y/y≈$1.00+108% y/y
Feb 23, 2021 Tue6:49 ambefore market openJan 29, 2021$7.8B+1% y/y$0.94−34% y/y
Nov 24, 2020 Tue6:50 ambefore market openOct 30, 2020$7.6B−1% y/y$0.36−64% y/y
Aug 25, 2020 Tue6:48 ambefore market openJul 31, 2020$6.5B−13% y/y$0.36−44% y/y
May 21, 2020 Thu6:48 ambefore market openApr 24, 2020$6.0B−26% y/y$0.48−45% y/y
Feb 18, 2020 Tue6:47 ambefore market openJan 24, 2020$7.7B+2% y/y$1.42+51% y/y
Nov 19, 2019 Tue6:48 ambefore market openOct 25, 2019$7.7B+3% y/y$1.01+23% y/y
Aug 20, 2019 Tue6:48 ambefore market openJul 26, 2019$7.5B+1% y/y$0.64−19% y/y
May 23, 2019 Thu6:49 ambefore market openApr 26, 2019$8.1B+0% y/y$0.87−19% y/y
Feb 19, 2019 Tue6:48 ambefore market openJan 25, 2019$7.5B+2% y/y$0.94
Nov 20, 2018 Tue6:48 ambefore market openOct 26, 2018$7.5B+6% y/y$0.82−45% y/y
Aug 21, 2018 Tue6:48 ambefore market openJul 27, 2018$7.4B−0% y/y$0.79+7% y/y
May 24, 2018 Thu6:49 ambefore market openApr 27, 2018$8.1B+3% y/y$1.07+27% y/y
Feb 20, 2018 Tue6:48 ambefore market openJan 26, 2018$7.4B+1% y/y−$1.03
Nov 8, 2017 Wed4:47 pmafter market closeOct 27, 2017$7.0B−4% y/y$1.48+85% y/y
Aug 22, 2017 Tue6:51 ambefore market openJul 28, 2017$7.4B+3% y/y$0.74+12% y/y
May 25, 2017 Thu6:50 ambefore market openApr 28, 2017$7.9B+5% y/y$0.84+8% y/y
Feb 21, 2017 Tue6:47 ambefore market openJan 27, 2017$7.3B+5% y/y$0.59−23% y/y
Nov 22, 2016 Tue6:47 ambefore market openOct 28, 2016$7.3B+4% y/y$0.80+122% y/y
Aug 25, 2016 Thu6:49 ambefore market openJul 29, 2016$7.2B−1% y/y$0.66+16% y/y
May 31, 2016 Tue6:47 ambefore market openApr 29, 2016$7.6B+4% y/y$0.78
Mar 1, 2016 Tue6:48 ambefore market openJan 29, 2016$6.9B+61% y/y$0.77−21% y/y
Dec 3, 2015 Thu6:48 ambefore market openOct 30, 2015$7.1B+62% y/y$0.36−57% y/y
Sep 3, 2015 Thu7:19 ambefore market openJul 31, 2015$7.3B+70% y/y$0.57−34% y/y
May 19, 2015 Tue8:34 ambefore market openApr 24, 2015$7.3B+60% y/y$0.00
Aug 19, 2014 Tue7:21 ambefore market openJul 25, 2014$4.3B+5% y/y$0.87−6% y/y
May 20, 2014 Tue7:20 ambefore market openApr 25, 2014$4.6B+2% y/y$0.44−54% y/y
Feb 18, 2014 Tue7:17 ambefore market openJan 24, 2014$4.2B+3% y/y$0.75−23% y/y
Nov 19, 2013 Tue7:19 ambefore market openOct 25, 2013$4.2B+2% y/y$0.89+41% y/y
Aug 20, 2013 Tue7:33 ambefore market openJul 26, 2013$4.1B+2% y/y$0.93+12% y/y
May 21, 2013 Tue7:20 ambefore market openApr 26, 2013$4.5B+4% y/y$0.95+1% y/y
Feb 19, 2013 Tue7:23 ambefore market openJan 25, 2013$4.0B+3% y/y$0.97+10% y/y
Nov 20, 2012 Tue7:26 ambefore market openOct 26, 2012$4.1B+2% y/y$0.63−23% y/y
Aug 21, 2012 Tue7:31 ambefore market openJul 27, 2012$4.0B+2% y/y$0.83+8% y/y
May 22, 2012 Tue7:34 ambefore market openApr 27, 2012$4.3B+3% y/y$0.94+31% y/y
Feb 21, 2012 Tue7:25 ambefore market openJan 27, 2012$3.9B+2% y/y$0.88+2% y/y
Nov 22, 2011 Tue7:26 ambefore market openOct 28, 2011$4.0B$0.82
Aug 23, 2011 Tue7:22 ambefore market openJul 29, 2011$3.9B$0.77
May 24, 2011 Tue7:22 ambefore market openApr 29, 2011$4.2B$0.72
Feb 22, 2011 Tue7:24 ambefore market openJan 28, 2011$3.9B$0.86
Show all 61 reports since 2011Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Medtronic: 16-year financials

FY202636,3646,4674,8015,4263,639
FY202533,5375,9554,6625,1853,589
FY202432,3645,1443,6765,2003,666
FY202331,2275,4853,7584,5803,616
FY202231,6865,7525,0395,9783,383
FY202130,1174,4843,6064,8853,120
FY202028,9134,7914,7896,0212,894
FY201930,5576,2684,6315,8732,693
FY201829,9536,6403,1043,6162,494
FY201729,7105,3834,0285,6262,376
FY201628,8335,3613,5384,1722,139
FY201520,2613,7662,6754,3311,337
FY201417,0053,8133,0654,5631,116
FY201316,5904,4023,4674,4851,055
FY201216,184—3,6173,9861,021
FY201115,508—3,0963,240969

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The company’s fiscal year doesn’t match the calendar year, so years follow the company’s own labels. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Medtronic: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202693,02849,46327,9611,94924,78711,658
202591,68048,02428,5162,21823,81412,879
202489,98150,21426,0971,28421,93510,789
202390,94851,48324,3641,54321,6759,051
202290,98152,55124,1143,71423,05912,394
202193,08351,42826,3893,59322,5488,509
202090,68950,73724,9164,14022,03110,366
201989,69450,09125,3904,39321,9678,472
201891,39350,72025,7503,66922,98010,084
201799,85750,20833,3684,96724,87314,264
201699,64452,06330,9372,87623,6007,165
2015106,68553,23035,5904,84330,8449,173
201437,94319,44311,8651,40321,2105,559
201334,90018,67110,09491917,8523,950
201232,81817,1139,3171,17216,3365,927

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

3 months ended 2026-07-31 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated1,7931,088+705
· incl. D&A (non-cash add-back)depreciation & amortization729748
· incl. stock-based comp (non-cash)share-based compensation12586
Capexpurchases of property & equipment−503−504+1
Free cash flow ≈operating cash flow − capex1,290584+706
Investing activities, netcapex, acquisitions, securities−1,619−719−900
· incl. acquisitionsbusinesses net of cash acquired−1,1620−1,162
Financing activities, netdebt, buybacks, dividends−343−1,381+1,038
· incl. buybacksrepurchases of common stock−267−123−144
· incl. dividends paid−921−910−11
FX effect on cash−8967−156
Net change in cash−258−945+687
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Jul 31, 2026: $50.2B (54% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Apr 2012Medtronic settled the Minneapolis Firefighters' Relief Association shareholder class action (INFUSE) for $85M. sec.gov ↗
  • Dec 2018The court approved the $43M settlement of the shareholder class action In re Medtronic Securities Litigation (INFUSE, 2013) — below the methodology's threshold. courtlistener.com ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Jun 2026FY2026 10-K: a single class of ordinary shares; share count −4.9% over 5 years, dividend up from $2.32 to $2.84. sec.gov ↗

Scoring: 2.0 −0.25 (criterion 9: shareholder suit over INFUSE settled for $85M in 2012, more than 10 years ago — half of 0.5) = 1.75 → rounded up to 2.0; the second INFUSE suit was settled in 2018 for $43M (< $50M — no deduction)

Share classes
Single class — MDT ordinary shares on the NYSE (cover of FY2026 10-K; an Irish plc).
Dilution
Diluted share count FY2021→FY2026 −4.9% (XBRL); SBC 1.3% of revenue.
Disclosure
Full 10-K/10-Q reporting.
Dividends
Dividend per share raised every year: $2.32 (FY2021) → $2.84 (FY2026); buybacks of $0.7–3.2B a year.
Lawsuits & regulators
The Minneapolis Firefighters suit (INFUSE, 2008) was settled for $85M (FY2012, more than 10 years ago); the West Virginia Pipe Trades suit (INFUSE, 2013) was settled in 2018 for $43M; class certification was denied in the suit over the Covidien deal (2020); no SEC disclosure cases.
Related parties
2026 proxy: a related-party transaction policy is in place, no material transactions disclosed; no controlling shareholder.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap · Piotroski F-score: S&P 500 companies scoring 8 or 9

Medtronic (MDT) earnings: FAQ

How does Medtronic make money?

Medtronic brought in $9.76 billion of revenue in Q1 2027, up 13.7% year over year. The largest source was Cardiovascular: $3.93 billion, or 40% of the total, followed by Neuroscience ($2.68B, 27%) and Medical Surgical ($2.28B, 23%); other lines add the remaining 9%. Net income for the quarter was $1.47 billion, up 41.4% year over year.

When is MDT's next earnings date?

Medtronic (MDT) is scheduled to report on Nov 24, 2026, before market open. The date was announced by the company (PR Newswire, Nov 4, 2026).

Company announcement ↗

What time does MDT report earnings?

Medtronic is scheduled to report before market open on Nov 24, 2026. Its last results releases came out before market open, most recently at 6:47 am ET on Sep 1, 2026.

When did MDT last report earnings?

Medtronic reported Q1 2027 results on Sep 1, 2026.

What has Medtronic guided for FY2027?

Company guidance for FY2027: revenue growth +7…8% (raised); EPS (non-GAAP) $5.94–6.00 (raised). A year ago (FY2026): revenue $36.4B, EPS (GAAP) $3.73. Source: the company's earnings release (Form 8-K filed Sep 1, 2026).

Where can I find Medtronic's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to MDT's filings; this page breaks the latest report down in a Sankey chart.

What was MDT's net income in Q1 2027?

Medtronic reported net income of $1,470M for Q1 2027 (+41.4% year over year), under US GAAP.

Does Medtronic pay dividends?

Yes. In fiscal 2026, Medtronic paid $3,639M in dividends on its common stock, per its 10-K. Earlier years are in the 16-year table above.

How has Medtronic's revenue changed since 2011?

Per its 10-K filings, revenue grew 2.3x: $15,508M in fiscal 2011 and $36,364M in fiscal 2026. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy